InspireMD (FRA:II2) Tax Provision : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is InspireMD Tax Provision?

InspireMD's tax provision for the three months ended in Dec. 2023 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

InspireMD Tax Provision Historical Data

The historical data trend for InspireMD's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Tax Provision Chart

InspireMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-0.02

-0.04

-0.03

-0.06

InspireMD Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Provision	Get a 7-Day Free Trial															-0.03	-	-	-	-

InspireMD Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

InspireMD (FRA:II2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (FRA:II2) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

NSPR:USA

Address

4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832

Website

https://www.inspiremd.com

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

InspireMD (FRA:II2) Headlines

No Headlines